» Articles » PMID: 33568991

Tissue Distribution of ACE2 Protein in Syrian Golden Hamster () and Its Possible Implications in SARS-CoV-2 Related Studies

Overview
Journal Front Pharmacol
Date 2021 Feb 11
PMID 33568991
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

The Syrian golden hamster () has recently been demonstrated as a clinically relevant animal model for SARS-CoV-2 infection. However, lack of knowledge about the tissue-specific expression pattern of various proteins in these animals and the unavailability of reagents like antibodies against this species hampers these models' optimal use. The major objective of our current study was to analyze the tissue-specific expression pattern of angiotensin-converting enzyme 2, a proven functional receptor for SARS-CoV-2 in different organs of the hamster. Using two different antibodies (MA5-32307 and AF933), we have conducted immunoblotting, immunohistochemistry, and immunofluorescence analysis to evaluate the ACE2 expression in different tissues of the hamster. Further, at the mRNA level, the expression of in tissues was evaluated through RT-qPCR analysis. Both the antibodies detected expression of ACE2 in kidney, small intestine, tongue, and liver. Epithelium of proximal tubules of kidney and surface epithelium of ileum expresses a very high amount of this protein. Surprisingly, analysis of stained tissue sections showed no detectable expression of ACE2 in the lung or tracheal epithelial cells. Similarly, all parts of the large intestine were negative for ACE2 expression. Analysis of tissues from different age groups and sex didn't show any obvious difference in ACE2 expression pattern or level. Together, our findings corroborate some of the earlier reports related to ACE2 expression patterns in human tissues and contradict others. We believe that this study's findings have provided evidence that demands further investigation to understand the predominant respiratory pathology of SARS-CoV-2 infection and disease.

Citing Articles

Gut microbe-host interactions in post-COVID syndrome: a debilitating or restorative partnership?.

Scheithauer T, Montijn R, Mieremet A Gut Microbes. 2024; 16(1):2402544.

PMID: 39287023 PMC: 11409505. DOI: 10.1080/19490976.2024.2402544.


Genome-scale CRISPR-Cas9 screen identifies host factors as potential therapeutic targets for SARS-CoV-2 infection.

Sakai M, Masuda Y, Tarumoto Y, Aihara N, Tsunoda Y, Iwata M iScience. 2024; 27(8):110475.

PMID: 39100693 PMC: 11295705. DOI: 10.1016/j.isci.2024.110475.


Ursodeoxycholic acid may protect from severe acute respiratory syndrome coronavirus 2 Omicron variant by reducing angiotensin-converting enzyme 2.

Lee K, Na Y, Kim M, Lee D, Choi J, Kim G Pharmacol Res Perspect. 2024; 12(2):e1194.

PMID: 38573021 PMC: 10993777. DOI: 10.1002/prp2.1194.


The Abundant Distribution and Duplication of SARS-CoV-2 in the Cerebrum and Lungs Promote a High Mortality Rate in Transgenic hACE2-C57 Mice.

Li H, Zhao X, Peng S, Li Y, Li J, Zheng H Int J Mol Sci. 2024; 25(2).

PMID: 38256071 PMC: 10815841. DOI: 10.3390/ijms25020997.


Mouse genome rewriting and tailoring of three important disease loci.

Zhang W, Golynker I, Brosh R, Fajardo A, Zhu Y, Wudzinska A Nature. 2023; 623(7986):423-431.

PMID: 37914927 PMC: 10632133. DOI: 10.1038/s41586-023-06675-4.


References
1.
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A . Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323(16):1574-1581. PMC: 7136855. DOI: 10.1001/jama.2020.5394. View

2.
Uhlen M, Bandrowski A, Carr S, Edwards A, Ellenberg J, Lundberg E . A proposal for validation of antibodies. Nat Methods. 2016; 13(10):823-7. PMC: 10335836. DOI: 10.1038/nmeth.3995. View

3.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

4.
Walls A, Park Y, Tortorici M, Wall A, McGuire A, Veesler D . Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020; 181(2):281-292.e6. PMC: 7102599. DOI: 10.1016/j.cell.2020.02.058. View

5.
Chan J, Zhang A, Yuan S, Poon V, Chan C, Lee A . Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility. Clin Infect Dis. 2020; 71(9):2428-2446. PMC: 7184405. DOI: 10.1093/cid/ciaa325. View